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COMPARISON OF BODY COMPOSITION ACCORDING TO AGE AND GENDER
IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD).
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The aim of the study was to compare: Body Cell Mass Index (BCMI), Lean
Tissue Index (LTI), Fat Tissue Index (FTI) measured by multifrequency
bioimpedance spectroscopy (Body Composition Monitor-FMC) according to
age and gender in patients with CKD stage 4-5 (NKF) without dialysis
treatment and in hemodialysis patients (HD). We included 45 adult
patients (pts) with CKD and eGFR o 30 ml/min not treated with dialysis -
predialysis group (26 male, age: 59,7 716,8) and 39 adults treated with
HD three times a week, for more than three months (26 male, age: 59,8
716,0). We deﬁned BCMI as Body Cell Mass divided by square body height
and analogically LTI and FTI (kg/m2). In statistics analysis we used
t-student test (SPSS v18).
Predialysis BCMI LTI FTI BMI
r 59 y 8,0 71,6 14,4 72,4 12,5 75,4 27,7 75,5
Z 60 y 6,4 71,4 11,9 72,0 15,8 75,0 28,5 74,8
Females 6,0 71,2 11,3 71,8 17,2 76,3 28,5 76,1
Male 7,9 71,5 14,2 72,1 12,7 73,5 28,0 74,0
In predialysis pts mean BCMI and LTI were signiﬁcantly lower in females
and older whereas BMI did not differ signiﬁcantly. Mean FTI was
signiﬁcantly higher in females (for all p o 0,05).
Hemodial. BCMI LTI FTI BMI
r 59 y 7,2 71,7 13,2 72,5 10,3 77,0 24,0 75,3
Z 60 y 5,8 71,4 11,3 71,9 13,3 74,9 25,4 74,4
Females 6,4 71,4 12,0 71,9 11,5 74,8 24,0 74,4
Males 6,4 71,8 12,2 72,6 12,2 76,6 25,1 75,0
In hemodialysis patients no signiﬁcant differences was observed in
females and males in all BCMI, LTI, FTI and BMI. BCMI, LTI were
signiﬁcantly lower in older pts whereas BMI did not differ signiﬁcantly (for
all p o 0,05). In both groups BCMI and LTI decline in patients over 60 years
whereas only in hemodialysis patients they do not differ in females and
males. Analysis of body composition in patients with CKD is worth to be
studied in large group of patients.
http://dx.doi.org/10.1016/j.krcp.2012.04.535
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EXAMINATION OF THE EFFECTS OF LIRAGLUTIDE ON
DIABETIC NEPHROPATHY
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Liraglutide (Lira), a glucagon-like peptide-1 receptor agonist, can be
administered to diabetic patients with renal failure without dose
reduction, but experience with the use of Lira in these patients is limited.
This study was designed to examine the effects of 6-month Lira
administration on glucose metabolism, body mass index (BMI), and renal
function in 18 patients with diabetic nephropathy (eGFR o60 ml/min).
The study included 18 patients with diabetic nephropathy who were on
insulin/oral hypoglycemic medications (6 men, 12 women; average age, 60
years; HbA1c, 8.4%; BMI, 29.4 7 8.2; duration of diabetes, 12 years; eGFR,
55.2 7 6.3 ml/min/1.73 m2). Lira was given either in combination or as
monotherapy. After 6 months of Lira treatment, changes in HbA1c levels,
casual blood glucose levels, BMI, and eGFR were examined.
The average HbA1c and casual blood glucose levels were signiﬁcantly
decreased after 6-month Lira administration (HbA1c before administration
8.4%, 7.9% at Month 1, 7.4% at Month 2, 7.1% at Month 3, 7.1% at Month 6; p
o 0.01 respectively, Paired T test). There were, however, no signiﬁcant
changes in renal function.
In conclusion, these results suggest that the administration of Lira in
patients with diabetic nephropathy may improve glucose metabolism and
reduce BMI without affecting renal function or albuminuria in the
short term.
http://dx.doi.org/10.1016/j.krcp.2012.04.536
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Fetuin-A is a calciﬁcation inhibitor, negative acute phase response
marker and cardiovascular mortality predictor in hemodialysis patients.
Low levels of fetuin-A are associated with malnutrition, inﬂammation,
decreased bone mass density, low-turnover bone and use of high calcium
concentration dialysate. Hemodialysis procedure (HD) has been shown to
decrease fetuin-A levels by 20%, probably due to HD-induced inﬂammation
or acute changes in calcium metabolism. The aim of our study was to
investigate effects of HD on serum fetuin-A levels. Forty clinically and
hemodynamically stable hemodialysis patients (21 females, 68 (38-85)
years) underwent routine bicarbonate hemodialysis or hemodiaﬁltration
with polysulfone dialyzer. On consecutive HD dialysis solution with
different calcium concentration with/without citric acid was used to assess
inﬂuence of calcium shifts and parathyroid activity on fetuin-A changes
during HD. All other parameters of HD were kept constant. Serum fetuin-A,
calcium, phosphorus, iPTH, CRP and other biochemical parameters were
measured before and after each HD. Our data show that predialysis serum
fetuin-A levels have positive correlation with iPTH levels (po0.05) and
tendency to decrease with higher CRP levels. There was no change in
fetuin-A levels during HD: 206 (167.1; 231.9) ug/ml before and 208.9
(170.3; 246.3) ug/ml after HD; respectively. When corrected for
haemoconcentration, decrease in fetuin-A was only 2.8% (po0.05). There
was also no difference between effect of hemodialysis and hemodia-
ﬁltration procedure. The use of different calcium dialysate concentrations
had distinct effect on iPTH levels during and after HD, however, we
observed no associated changes in fetuin-A levels. The use of dialysate
solution with citric acid had no effect on fetuin-A levels. In conclusion,
standard bicarbonate HD with polysulfone dialyser and ultrapure dialysate
induces only minor changes in fetuin-A and no changes in hsCRP levels.
iPTH levels correlate positively with predialysis fetuin-A, but distinct acute
changes in iPTH secretion induced by different dialysate calcium
concentrations have no effect on serum fetuin-A levels after a single HD.
http://dx.doi.org/10.1016/j.krcp.2012.04.537
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OUTCOME OF ZINC SUPPLEMENTATION ON NUTRITIONAL INTAKE OF
CKD PATIENTS
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Zn, which might help in improving appetite/dietary intake by reducing
taste abnormalities, is mostly available in protein rich foods. Pre-dialysis
chronic kidney disease patients are advised low protein diet. This study
was aimed to assess Zn status & inﬂuence of Zn supplementation on
nutritional intake/appetite of 100 predialysis CKD patients not formally
counseled for diet. 40 apparently healthy controls were included in the
study. In group I (n¼50), Zn sulphate (20mg elemental Zn) alone was given
while dietary counseling [calories 35–40Kcal/kg bodyweight, proteins 0.6–
0.8g/kg bodyweight (450% high biological value)] along with Zn
supplementation was given to group II (n¼50). Statistical signiﬁcance was
calculated using SPSS Inc. version 15.0. Signiﬁcantly lower nutritional & Zn
status (pr0.001) in CKD pts. as compared to controls was observed. After
1month of respective interventions, only group-II patients showed
improvement in nutritional status [energy pr0.001, protein pr0.05, Zn
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